How is Merck doing financially?
Merck KGaA, headquartered in Darmstadt, Germany, is the original and oldest pharmaceutical and chemical company in the world, founded in 1668. Conversely, Merck & Co., Inc., based in Rahway, New Jersey, originated as an American subsidiary of the German parent company before being sequestered and made completely independent following World War I. Today, they operate as entirely separate, unrelated corporate entities. Due to historical trademark litigation, Merck KGaA holds the exclusive rights to the name "Merck" globally, whereas the American firm must operate under the brand name Merck Sharp & Dohme (MSD) outside of the United States and Canada.
Related FAQs
Warren Buffett maintains a massive, multi-billion-dollar equity investment in Moody's Corporation (MCO), representing one of Berkshire Hathaway's longest-standing portfolio cornerstones.
Merck & Co.
Determining whether Merck & Co. is overvalued involves analyzing its forward price-to-earnings multiples relative to projected earnings growth and the looming patent expiration of its top-selling cancer immunotherapy, Keytruda.
Wall Street equity analysts generally evaluate Merck stock as a moderate buy, reflecting a balance between its defensive healthcare appeal, reliable dividend payouts, and upcoming pipeline catalysts against looming patent expirations for Keytruda.
Equity research analysts tracking Merck & Co.
Merck & Co. is widely regarded by healthcare and dividend growth investors as an exceptional long-term holding, underpinned by its essential role in global biopharmaceutical innovation.